In accordance with these results, flow cytometry analysis displayed a similar expression pattern in primary implanted and regrown tumors, indicating a shift toward CD86 marker expression shortly after tumor resection and then another shift towards high expression of both CD206 and CD86 in fully regrown tumors (Figure 5). The gene discussed is MRC1; the disease is neoplasm.